by caryn » Tue Jan 24, 2012 03:18 am
Identification of antiangiogenic, autoimmune, and inflammatory factors produced in response to placental ischemia have provided potential new avenues for future research into novel therapies for the preeclamptic patient, and suggest new therapeutic avenues for the treatment of preeclampsia.http://www.ncbi.nlm.nih.gov/pubmed/22257796Just another "oh hey, it's likely to be soluble FLT and soluble endoglin triggering a pissed-off maternal immune system after the placenta runs short of blood" abstract.

[i]Identification of antiangiogenic, autoimmune, and inflammatory factors produced in response to placental ischemia have provided potential new avenues for future research into novel therapies for the preeclamptic patient, and suggest new therapeutic avenues for the treatment of preeclampsia.[/i]
http://www.ncbi.nlm.nih.gov/pubmed/22257796
Just another "oh hey, it's likely to be soluble FLT and soluble endoglin triggering a pissed-off maternal immune system after the placenta runs short of blood" abstract. :D